Why Is NOVARTIS AG ADR (NVS) Stock Moving Today?

Why NVS stock is down today

Novartis AG ADR (NVS) fell 13.93% to $137.70 in a session marked by a significant blow to its drug development pipeline. The stock’s worst day in over two decades came after the company announced the failure of its experimental cholesterol drug del-desiran in a late-stage trial. This setback has raised concerns about the broader Lp(a) drug class, affecting not only Novartis but also competitors like Amgen and Eli Lilly.

What Happened

The company disclosed on Tuesday that del-desiran did not meet its primary endpoint in a key cardiovascular trial. This is the second major trial failure in a week for Novartis, further deepening investor concerns. The failure of the drug has cast a shadow over the company’s prospects in the cholesterol treatment market and triggered a broad sell-off in related biotech stocks. Mizuho analysts noted that the selloff in Sarepta shares following the Novartis setback appears overdone, but the market has not yet found a floor. Deutsche Bank downgraded the stock to Hold from Buy, while RBC Capital initiated coverage with a Sector Perform rating. The stock’s sharp decline has also led to a broader market reaction, with Amgen falling 10% as investors reevaluated the entire Lp(a) drug class.

What The Data Shows

The stock has declined 11.1% over the past eight sessions, moving from $155.21 to $137.98. On September 8, the stock printed two fresh 52-week highs and 21 fresh 52-week lows, highlighting the volatility. The current price of $137.70 is within the 52-week range of $121.57 to $170.46. The stock’s beta of 0.49 suggests it is less volatile than the market, yet the recent drop has been severe. Retail traders on social media platforms have noted the stock’s underperformance, with some calling it oversold. Congressional trades show recent activity, with Senator Alan Armstrong buying shares in the $1,001-$50,000 range on March 30 and March 31.

What To Watch

The stock is currently without an upcoming earnings report, so coverage breadth and analyst reactions to the trial failure will be key to watch in the coming days.

Why is NVS stock moving today?

NOVARTIS AG ADR (NVS) is drawing unusual attention today. Our newswire has captured 33 stories on NVS across 17 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100). The most recent driver: "Novartis price target raised to CHF 130 from CHF 120 at RBC Capital" (The Fly).

Is NVS a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NVS coverage reads 60/100 over 33 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.